Beatrice Detti

Beatrice Detti

Auto-generated profile, based on publicly available information

Beatrice Detti

Radiation Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2018 in Seminars in Oncology
Verified
Journal Article
Closed access
Gianluca IngrossoGianluca Ingrosso
Gianluca Ingrosso
BDBeatrice Detti
Beatrice Detti
DSDaniele Scartoni
Daniele Scartoni
Andrea LanciaAndrea Lancia
Andrea Lancia
IGIrene Giacomelli
Irene Giacomelli
RSRiccardo Santoni
Riccardo Santoni

22 June 2023 in Strahlentherapie und Onkologie
Verified
Journal Article
Open access
PDF file
CBCarlotta Becherini
Carlotta Becherini
Andrea LanciaAndrea Lancia
Andrea Lancia
BDBeatrice Detti
Beatrice Detti
SLSARA LUCIDI
SARA LUCIDI
DSDaniele Scartoni
Daniele Scartoni
LLLorenzo Livi
Lorenzo Livi
Objective: Tumor-associated macrophages (TAMs) are the most represented cells of the immune system in the tumor microenvironment (TME). Besides its effects on cancer cells, radiation therapy (RT) can alter TME composition. With this systematic review, we provide a better understanding on how RT can regulate macrophage characterization, namely the M1 antitumor and the M2 protumor polarization, with the aim of describing new effective RT models and exploration of the possibility of integrating radiation with other available therapies. Methods: A systematic search in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was carried out in PubMed, Google Scholar, and Scopus. Articles from January 2000 to April 2020 which focus on the role of M1 and M2 macrophages in the response to RT were identified. Results: Of the 304 selected articles, 29 qualitative summary papers were included in our analysis (16 focusing on administration of RT and concomitant systemic molecules, and 13 reporting on RT alone). Based on dose intensity, irradiation was classified into low (low-dose irradiation, LDI; corresponding to less than 1 Gy), moderate (moderate-dose irradiation, MDI; between 1 and 10 Gy), and high (high-dose irradiation, HDI; greater than 10 Gy). While HDI seems to be responsible for induced angiogenesis and accelerated tumor growth through early M2-polarized TAM infiltration, MDI stimulates phagocytosis and local LDI may represent a valid treatment option for possible combination with cancer immunotherapeutic agents. Conclusion: TAMs seem to have an ambivalent role on the efficacy of cancer treatment. Radiation therapy, which exerts its main antitumor activity via cell killing, can in turn interfere with TAM characterization through different modalities. The plasticity of TAMs makes them an attractive target for anticancer therapies and more research should be conducted to explore this potential therapeutic strategy.

18 September 2013 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
BDBeatrice Detti
Beatrice Detti
SSSilvia Scoccianti
Silvia Scoccianti
VCVanessa Di Cataldo
Vanessa Di Cataldo
EMEleonora Monteleone
Eleonora Monteleone
SCSamantha Cipressi
Samantha Cipressi
GBGiampaolo Biti
Giampaolo Biti

7 July 2015 in BMC Urology
Verified
Journal Article
Open access
PDF file
Mauro GacciMauro Gacci
Mauro Gacci
OSOmar Saleh
Omar Saleh
CGClaudia Giannessi
Claudia Giannessi
BDBeatrice Detti
Beatrice Detti
LLLorenzo Livi
Lorenzo Livi
SSSergio Serni
Sergio Serni
Radiotherapy is one of the treatment options for prostate cancer (PCa) but up to 25 % of men report about severe nocturia (nocturnal voiding). The combination of hyaluronic acid (HA) and chondroitin sulfate (CS) resembles glycosaminoglycan (GAG) replenishment therapy. The aim of our study was to evaluate the impact of HA and CS on nocturia, in men with nocturia after PCa radiotherapy. Twenty-three consecutive patients with symptomatic cystitis after external radiotherapy for PCa were enrolled. Patients underwent bladder instillation therapy with HA and CS weekly for the first month and, afterwards, on week 6, 8 and 12. Nocturnal voiding frequency was assessed by item 3 (Q3) of the Interstitial Cystitis Symptoms Index (ICSI) and item 2 (Q2) of the Interstitial Cystitis Problem Index (ICPI). Data were analyzed with paired-samples T-test and adjusted for age. Eighteen patients (78 %) reported about nocturia. Pre- and post-treatment ICSI-Q3 was 2.13 ± 0.28 and 1.61 ± 0.21 (−24.4 %, p = 0.001). With logistic regression analysis, both age and baseline ICSI-Q3 had a significant impact on nocturnal voiding frequency (r = 0.293, p = 0.011 and r = 0.970, p < 0.001). Pre- and post-treatment ICPI-Q2 was 1.87 ± 0.26 and 1.30 ± 0.25 (−30.5 %, p = 0.016); logistic regression analysis was without significant findings. Bladder instillation treatment with a combination of HA and CS was effective in reducing nocturnal voiding frequency in men with post-radiation bladder pain for PCa. Randomized, controlled trials with sham treatment are needed to confirm our result.

1 September 2021 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
GFGiulio Francolini
Giulio Francolini
BDB. Detti
B. Detti
CBC. Becherini
C. Becherini
SCS. Caini
S. Caini
GIG. Ingrosso
G. Ingrosso
LLL. Livi
L. Livi

11 August 2022 in La radiologia medica
Verified
Journal Article
Open access
PDF file
BDBeatrice Detti
Beatrice Detti
SSSilvia Scoccianti
Silvia Scoccianti
VMVirginia Maragna
Virginia Maragna
SLSara Lucidi
Sara Lucidi
MGMichele Ganovelli
Michele Ganovelli
LLLorenzo Livi
Lorenzo Livi
Background: Pleomorphic xanthoastrocytoma (PXA) is a rare low-grade brain tumor. To date, limited studies have analyzed factors affecting survival outcomes and defined the therapeutic strategy. The aim of this retrospective analysis was to investigate the clinicopathologic characteristics of PXA and identify factors associated with outcomes. Methods: We retrospectively analyzed a cohort of 16 adult and children patients with PXA who underwent primary resection from 1997 to 2019, referred to our Radiation Oncology Unit and to Meyer’s Paediatric Hospital. We also reviewed the relevant literature. Results: All patients underwent primary surgical resection; 10 patients received adjuvant radiation treatment course, ranging from DTF 54 to 64 Gy; 8 of them received, in addition, concurrent adjuvant chemotherapy; 6 patients underwent only radiological follow-up. After a median follow up was 60 months: median OS was 34.9 months (95% CI 30–218), 1-year OS 87%, 5-years OS 50%, 10-years OS 50%; median PFS 24.4 months (95% CI 13–156), 1-year PFS 80%, 5-years PFS 33%, 10-years PFS 33%. A chi-square test showed a significant association between OS and recurrent disease (p = 0.002) and with chemotherapy adjuvant treatment (p = 0.049). A borderline statistical significant association was instead recognized with BRAF mutation (p = 0.058). Conclusions: Despite our analysis did not reveal a strong prognostic or predictive factor able to address pleomorphic xanthoastrocytoma management; however, in selected patients could be considered the addition of adjuvant radiation chemotherapy treatment after adequate neurosurgical primary resection. Furthermore, recurrent disease evidenced a detrimental impact on survival.